Distal ulcerative colitis in mild to moderate active phase
Conditions
Interventions
control group:Basic treatment+Salofalk (Mesalqin enema)
experimental group:Basic treatment+HKE
Sponsors
Jiangsu Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Meet the Western diagnostic criteria of UC: a. staging; b. mild to moderate; c. range of rectal or left colon; d.Mayo score 3-10, and Mayo endoscopic subscore above 2; (2) TCM syndrome differentiation is dampness-heat and intestinal syndrome or spleen deficiency and dampness syndrome; (3) Between 18 and 65 years old; (4) The patient himself has voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: amoebic dysentery chronic schistosomiasis intestinal tuberculosis and other infectious colitis Crohn's disease ischemic enteritis and radiation enteritis; (2) Patients with serious complications such as local stenosis intestinal obstruction intestinal perforation toxic colon dilatation massive bleeding colon cancer and rectal cancer; (3) Patients with other primary and secondary infectious diseases such as cholecystitis and pneumonia; (4) Those with a history of enema treatment within half a month; (5)They are currently being treated with glucocorticoids thiopurine drugs biological agents and probiotics; (6) Patients with serious cardiovascular liver gallbladder lung kidney and blood system diseases; (7) Allergic constitution such as a history of allergy to two or more drugs or food or a known allergy to investigational drugs; (8) Suspected or definite history of alcohol or drug abuse; (9) women during pregnancy or lactation; (10) Disabled patients (blind deaf dumb intellectual disabilities mental disorders physical disabilities); (11) According to the judgment of the researcher there are other lesions that reduce the possibility of enrollment or complicate the enrollment such as frequent changes in the working environment which are easy to cause loss to follow-up; (12) Patients who have participated in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy (clinical response rate clinical response efficiency);Efficacy of colonoscopy (endoscopic response rate mucosal healing rate); | — |
Secondary
| Measure | Time frame |
|---|---|
| Integration improvement and disappearance rate of individual symptoms;Changes from baseline in CRP ESR and fecal calferin;Efficacy of TCM syndrome;Endoscopic mucosal healing rate; | — |
Countries
China
Contacts
Public ContactChen Yugen
Jiangsu Provincial Hospital of Chinese Medicine
Outcome results
None listed